# Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHL

> **NCT00577161** · PHASE3 · WITHDRAWN · sponsor: **CTI BioPharma**

## Conditions studied

- Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** fludarabine and rituximab
- **DRUG:** fludarabine, rituximab, pixantrone

## Key facts

- **NCT ID:** NCT00577161
- **Lead sponsor:** CTI BioPharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2007-09
- **Primary completion:** 2012-07
- **Final completion:** 2012-07
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** closed to enrollment
- **Last updated:** 2020-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00577161

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00577161, "Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHL". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT00577161. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*